Hydrogel capable of instantly solidifying
A hydrogel with a PEG-based first and polypeptide-based second network structure achieves rapid gelation and cell compatibility, addressing the challenge of forming hydrogels on complex tissues by solidifying instantly and ensuring cell adhesion and survival.
Patent Information
- Application Number
- PCT/JP2024/018504
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-20
- Publication Date
- 2024-12-05
AI Technical Summary
Conventional hydrogel materials take several minutes to gel in a neutral pH environment, making it difficult to form hydrogels on complex or sloped living tissue surfaces, as the gelling solution flows out before solidification, and existing materials lack both rapid gelation and cell compatibility.
A hydrogel composition with a first polymer network crosslinked by polyethylene glycol (PEG) and a second polymer network crosslinked with a polypeptide, achieving rapid gelation within 10 seconds and maintaining cell compatibility and tissue adhesion, suitable for spraying onto biological surfaces.
The hydrogel solidifies instantly upon application, preventing flow and allowing effective immobilization of cells on complex surfaces, with excellent cell adhesion and protein permeability, enabling stable cell survival and tissue integration.
Smart Images

Figure JP2024018504_05122024_PF_FP_ABST
Abstract
Description
Instantly solidifying hydrogel
[0001] The present invention relates to a tissue-adhesive hydrogel that can be instantly solidified by spraying or the like, and a kit for forming the hydrogel.
[0002] Hydrogels are polymeric materials composed of cross-linked polymers and water. They are highly permeable to molecules essential for living cells, such as salts and proteins, and are therefore used as scaffolds for cells. Polymers that make up such hydrogel scaffolds can include naturally occurring collagen, gelatin, fibrinogen / thrombin, polysaccharides, or synthetic polymers such as poly(acrylamide) and poly(ethylene glycol) (PEG) (see, for example, Non-Patent Document 1). Alginate is also a rapidly gelling material. However, alginate gels generally do not exhibit cell adhesive properties and are therefore unsuitable as scaffolds for cell adhesion.
[0003] Gelatin has been widely studied as an artificial extracellular matrix (ECM) because its high water solubility and cell adhesion properties make it suitable for cell-related manipulations (e.g., Non-Patent Document 2). Gelatin is also characterized by the fact that the risk of contamination with unknown viruses is minimized compared to other protein-derived products by applying strict chemical and physical treatments during the manufacturing process.
[0004] Although attempts have been made to gel gelatin by crosslinking lysine residues in gelatin with synthetic polymers, the gelation time required several minutes at neutral pH, making it difficult to form ECM gels in situ. In cases of such slow gelation, the gelling solution flows out before solidifying, making it impossible to form hydrogels on the surfaces of biological tissues with complex shapes or inclined surfaces. Therefore, a hydrogel material that can gel in a short time in a neutral pH environment, ideal for living cells, and that is both cytocompatible and tissue-adhesive has yet to be developed.
[0005] Asadi et al., Mater. Chem. Phys. 2020, 242, 122528. Su et al., Biotechnol. Lett. 2015, 37 (11), 2139-2145.
[0006] Therefore, an object of the present invention is to provide a hydrogel material that can be gelled in situ in a short time using a general-purpose means such as spraying, and that has cytocompatibility and tissue adhesiveness.
[0007] As a result of extensive research aimed at solving the above-mentioned problems, the present inventors have found that by forming a hydrogel having two network structures, namely, a first polymer network formed by crosslinking a homogeneous polymer having a polyethylene glycol (PEG) backbone and a second polymer network formed by crosslinking a heterogeneous polymer, i.e., a polypeptide and a PEG backbone polymer, a material that solidifies in a short time and has cytocompatibility and tissue adhesiveness can be provided. Furthermore, they have found that by supporting (encapsulating) cells such as stem cells in such a hydrogel, the hydrogel can be suitably used as a scaffold for cell adhesion, and the hydrogel composition containing desired cells can be effectively immobilized in a target biological tissue. Based on these findings, the present invention has been completed.
[0008] That is, in one aspect, the present invention relates to a hydrogel, a scaffold for cell adhesion comprising the hydrogel, and a gel composition in which cells are supported on the hydrogel, and includes: <1> a hydrogel comprising a first polymer network formed by chemically crosslinking two or more types of polymers (PEG-A) having a polyethylene glycol backbone, and a second polymer network formed by chemically crosslinking a polypeptide and a polymer (PEG-B) having a polyethylene glycol backbone; <2> the hydrogel according to <1> above, having a gelation time within a range of 10 seconds, wherein the gelation time is the time required for the storage modulus G' and the loss modulus G" to reach G' = G"; <3> the hydrogel according to <1> above, wherein the concentration of the polypeptide in the second polymer network in the hydrogel is 10 g / L or more and 120 g / L or less; <4> the hydrogel according to <1> above, wherein the total content of polymers having a polyethylene glycol backbone (PEG-A and PEG-B) in the hydrogel is 15 g / L or more; <5> The hydrogel according to <1> above, wherein the first polymer network has a cleavable site selected from the group consisting of an ester bond, a thioester bond, a disulfide bond, a phosphate ester bond, a sulfonate ester bond, and combinations thereof; <6> The hydrogel according to <1> above, wherein the polymer (PEG-A) having a polyethylene glycol backbone in the first polymer network comprises a first polymer having a total of two or more nucleophilic functional groups at a side chain or end, and a second polymer having a total of two or more electrophilic functional groups at a side chain or end; <7> The hydrogel according to <1> above, wherein the polymer (PEG-B) having a polyethylene glycol backbone in the second polymer network has a total of two or more electrophilic functional groups at a side chain or end that can react with an amino group present in the polypeptide molecule to form an amide bond or a urethane bond; <8> The hydrogel according to the above <1>, wherein the polypeptide is one or more selected from the group consisting of gelatin, collagen, albumin, laminin, fibrinogen, elastin, fibronectin, and derivatives thereof;<9> The hydrogel according to <1> above, wherein the concentration of the polypeptide in the hydrogel is 10 g / L or more and the concentration of the polymer having a polyethylene glycol backbone (PEG-B) in the second polymer network is 15 g / L or more; <10> The hydrogel according to <1> above, wherein the pH of the solvent contained in the hydrogel is in the range of 6.5 to 11.5; <11> A scaffold material for cell adhesion, comprising the hydrogel according to any one of <1> to <10> above; <12> A gel composition comprising cells supported in the hydrogel according to any one of <1> to <10> above; and <13> The gel composition according to <11> above, wherein the cells are somatic stem cells.
[0009] In another aspect, the present invention relates to a kit containing raw polymer solutions for forming the above-mentioned hydrogel, specifically: <14> A kit for rapidly preparing a hydrogel, which contains a solution X containing polymers A and B and a solution Y containing a polypeptide and a polymer C, separately stored therein, wherein the polymer A is a polymer having a polyethylene glycol backbone capable of chemically crosslinking with the polypeptide, and the polymers B and C are a combination of polymers having polyethylene glycol backbones capable of chemically crosslinking with each other, and the gelation time of the hydrogel obtained by mixing the solutions X and Y is within 10 seconds, wherein the gelation time is the time required for the storage modulus G' and the loss modulus G" to reach G'=G"; <15> The kit according to the above <14>, wherein the polymer A has, at a side chain or terminal, a total of two or more electrophilic functional groups capable of reacting with an amino group present in the polypeptide molecule to form an amide bond or a urethane bond; <16> The kit according to the above <14>, wherein the polymers B and C are a combination of a polymer having a total of two or more nucleophilic functional groups at the side chain or end and a polymer having a total of two or more electrophilic functional groups at the side chain or end; <17> The kit according to the above <14>, wherein the polypeptide in the solution Y is one or more selected from the group consisting of gelatin, collagen, albumin, laminin, fibrinogen, elastin, fibronectin, or derivatives thereof; <18> The kit according to the above <14>, wherein the reaction rate of the polymer B and the polymer C is in the range of 60% to 100%; <19> The kit according to the above <14>, for spraying the solutions X and Y onto a predetermined area with a sprayer; and <20> The kit according to the above <14>, wherein the solutions X and Y are stored in separate sprayers.
[0010] According to the present invention, a novel hydrogel can be provided that solidifies in situ in a short time and has cytocompatibility and tissue adhesiveness. The hydrogel of the present invention solidifies almost instantly, typically within a few seconds, when sprayed onto a biological surface, while maintaining excellent cell adhesiveness derived from the polypeptide component in the gel.
[0011] Furthermore, by incorporating cells such as stem cells into the hydrogel, it can be used favorably as a scaffold for cell adhesion and can effectively immobilize desired cells in target biological tissue. Because it solidifies almost instantly after application to the biological tissue by spraying or other methods, it does not flow out before gelation as with conventional gel materials, and can be applied to affected areas with complex shapes or inclined surfaces. The hydrogel is protein permeable, allowing cells incorporated (encapsulated) in the gel to survive stably for a long period of time.
[0012] FIG. 1(A) is a photograph and a schematic diagram of the structure of a hydrogel (GP) composed of gelatin and PEG-NHS; FIG. 1(B) is a graph showing the gelation times of Comparative Examples 16, 17, and 18; and FIG. 1(C) is a graph showing the changes in storage modulus (G') and loss modulus (G") over time of Comparative Example 17. FIG. 2(A) is a photograph and a schematic diagram of the structure of a hydrogel (PP) composed of PEG-SH and PEG-MA; FIG. 2(B) is a graph showing the gelation times of Reference Examples 1, 2, 3, and 4; and FIG. 2(c) is a graph showing the changes in storage modulus (G') and loss modulus (G") over time of Reference Example 3. 3A is a photograph and a schematic diagram of the structure of a hydrogel (GP / PP) composed of gelatin / PEG-SH and PEG-NHS / PEG-MA; FIG. 3B is a graph showing the change over time in the storage modulus (G') and loss modulus (G") of Example 3. FIG. 4 is a graph showing the modulus (G') of the hydrogels of Comparative Example 17, Reference Example 3, and Example 3. FIG. 5 is an image showing the process of forming the hydrogel of Example 3 using a sprayer. FIG. 6 is a representative photograph (left) of GP / PP (ester), which is the hydrogel of Example 3 that has been made hydrolyzable, in a collagenase solution and an alkaline aqueous solution, and a graph (right) showing the swelling degree (Q) of the hydrogel. FIG. 7 is a glass plate with a collagen casing fixed (upper left), a schematic diagram of the chemical reaction at the interface between the GP hydrogel and the collagen casing (upper right), and a graph showing the results of a lap shear test. A schematic diagram of the test specimen (bottom) is shown. Figure 8 shows a representative photograph of the test specimen set in the tensile tester (left), a graph showing the typical relationship between lap shear strength and displacement (center), and a graph showing the lap shear strength at break for each hydrogel (right). Figure 9(A) shows the apparatus for simultaneously spraying human mesenchymal stem cells (hMSCs) and hydrogel components (left) and a fluorescent image of hMSCs encapsulated in the hydrogel (right; scale bar indicates 100 μm). Figure 9(B) shows a graph showing the viability of hMSCs cultured in each hydrogel. Figure 10 shows the experimental procedure for adding fluorescein isothiocyanate-labeled bovine serum albumin (BSA-FITC) to the culture medium (left), and a fluorescent image of hMSCs cultured in BSA-FITC (right; 200x and 400x magnifications indicate magnification; scale bar indicates 40 μm).
[0013] The following describes embodiments of the present invention. The scope of the present invention is not limited to these descriptions, and other than the following examples, the present invention can be implemented with appropriate modifications within the scope that does not depart from the spirit of the present invention.
[0014] 1. Hydrogel of the Present Invention The hydrogel of the present invention is characterized by having the following two types of network structures: i) a first polymer network formed by chemically crosslinking two or more types of polymers (PEG-A) having a polyethylene glycol (PEG) backbone; and ii) a second polymer network formed by chemically crosslinking a polypeptide and a polymer (PEG-B) having a polyethylene glycol backbone.
[0015] That is, the first polymer network is a network structure formed by crosslinking polymers each having a PEG backbone, while the second polymer network is a network structure formed by crosslinking a different polymer, a polypeptide molecule and a PEG polymer. This achieves a shortened gelation time and solidification in a short time, which were problems with conventional techniques, while maintaining the cytocompatibility and tissue adhesiveness inherent in the polypeptide component.
[0016] In this specification, the term "gel" generally refers to a dispersion system of polymers that has high viscosity and has lost fluidity, and is in a state where the storage modulus G' and the loss modulus G" satisfy the relationship G'≧G", and is typically a substance with a three-dimensional network structure. The term "hydrogel" refers to a state in which the gel contains a solvent such as water inside. Preferably, the solvent is water.
[0017] The hydrogel of the present invention preferably has a gelation time of 10 seconds or less, more preferably in the range of 1 to 10 seconds. Because the hydrogel of the present invention gels in a short time and solidifies almost instantaneously, unlike conventional gel materials, the pre-gel solution does not flow out or to the surrounding area, and can be applied to affected areas with complex shapes or inclined surfaces. Here, "gelation time" refers to the time from mixing a solution containing raw polymers until gelation occurs, and is the time required for the storage modulus G' and loss modulus G" to become equal to G' = G". The gelation time can be further adjusted mainly by appropriately setting the polymer concentration, pH, and ionic strength of the polymer solution.
[0018] As described above, the solvent contained in the hydrogel of the present invention is typically water, but in some cases it can be a mixed solvent containing a trace amount of alcohol such as ethanol or other organic solvent. The pH of the solvent contained in the hydrogel is in the range of 6.5 to 11.5, more preferably in the range of 7.0 to 10.5, and preferably in the range of 7.0 to 8.5.
[0019] 1-1 PEG Polymer Both PEG-A and PEG-B in the hydrogel of the present invention are polymers having a polyethylene glycol backbone. A "polymer having a polyethylene glycol backbone" (hereinafter sometimes simply referred to as a "PEG polymer") typically includes polymer species having multiple branches of the polyethylene glycol backbone, and preferred examples include di-, tri-, tetra-, or octa-branched polyethylene glycols. In particular, gels consisting of a tetra-branched polyethylene glycol backbone are generally known as tetra-PEG gels, and a mesh-structure network is constructed by an AB cross-end coupling reaction between two types of tetra-branched polymers each having an electrophilic functional group such as an active ester structure and a nucleophilic functional group such as an amino group at their termini (Matsunaga et al., Macromolecules, Vol. 42, No. 4, pp. 1344-1351, 2009). Furthermore, Tetra-PEG gels can be easily prepared in situ by simply mixing two polymer solutions, and the gelation time can be controlled by adjusting the pH and ionic strength during gel preparation. Furthermore, gels based on PEG are also highly biocompatible.
[0020] The first polymer network is formed by chemically crosslinking two or more types of PEG polymers (PEG-A) with each other to form a three-dimensional network structure. Typically, the PEG polymers (PEG-A) forming the first polymer network include a first polymer having a total of two or more nucleophilic functional groups at the side chains or ends, and a second polymer having a total of two or more electrophilic functional groups at the side chains or ends. A gel is formed by crosslinking such nucleophilic functional groups and electrophilic functional groups. Here, the total number of nucleophilic functional groups and electrophilic functional groups is preferably five or more. It is more preferable that these functional groups are present at the ends.
[0021] Examples of the nucleophilic functional group include a thiol group (sulfhydryl group) (-SH) and an amino group, and those skilled in the art can appropriately use known nucleophilic functional groups. Preferably, the nucleophilic functional group is a -SH group. The nucleophilic functional groups may be the same or different, but it is preferable that they are the same. When the functional groups are the same, the reactivity with the electrophilic functional groups that form crosslinks becomes uniform, making it easier to obtain a gel with a uniform three-dimensional structure.
[0022] The electrophilic functional group may be a functional group that can be attacked by a nucleophilic functional group, such as a maleimide group, an N-hydroxy-succinimidyl (NHS) group, a succinimidyl carbonate group, a sulfosuccinimidyl group, a phthalimidyl group, an imidazolyl group, an acryloyl group, a nitrophenyl group, a —CO 2 PhNO 2 (Ph represents an o-, m-, or p-phenylene group), and those skilled in the art can appropriately use other known electrophilic functional groups. Preferably, the electrophilic functional group is a maleimide group, an N-hydroxysuccinimidyl (NHS) group, or a succinimidyl carbonate group. When the nucleophilic functional group is a thiol group, a maleimide group is particularly preferred as the electrophilic functional group, and when the nucleophilic functional group is an amino group, an N-hydroxysuccinimidyl (NHS) group or a succinimidyl carbonate group is particularly preferred as the electrophilic functional group. The electrophilic functional groups may be the same or different, but are preferably the same. When the functional groups are the same, the reactivity with the nucleophilic functional group that forms the crosslinked bond becomes uniform, making it easier to obtain a gel with a uniform three-dimensional structure.
[0023] The crosslinking method for forming the hydrogel is not limited to the reaction between the nucleophilic functional group and the electrophilic functional group, and those skilled in the art can select other known chemically crosslinkable pairs.
[0024] In a preferred embodiment, the first polymer network can have a bond that can be cleaved by hydrolysis or the like. That is, the first polymer network can have a cleavable site selected from the group consisting of an ester bond, a thioester bond, a disulfide bond, a phosphate ester bond, a sulfonate ester bond, and combinations thereof. The cleavable site can be a linker moiety connecting the polyethylene glycol backbone and the above-mentioned nucleophilic / electrophilic functional group. Alternatively, it can be present at a crosslinking position between PEG-A.
[0025] The PEG polymer (PEG-B) that forms the second polymer network is similar to the PEG-A in that it also has a polyethylene glycol backbone. The PEG-B forms the second polymer network by chemically crosslinking with the polypeptide. Therefore, the PEG-B typically has a total of two or more electrophilic functional groups at its side chains or ends that can react with amino groups present in the polypeptide molecule to form amide bonds or urethane bonds. The types of such electrophilic functional groups are as described above.
[0026] PEG-A and PEG-B were each independently 1 x 10 3 ~1x10 5 range, preferably 0.5 x 10 4 ~5x10 4 in the range of 1×10 4 ~2x10 4 The weight average molecular weight (Mw) ranges from 100 to 1500.
[0027] Non-limiting examples of preferred PEG polymers having a nucleophilic functional group at their termini (i.e., the first polymer of PEG-A) include compounds represented by the following formula (I), which have four branches of a polyethylene glycol backbone and a thiol group at their termini:
[0028] In formula (I), R 11 ~R 14 are the same or different, and C 1 -C 7 Alkylene group, C 2 -C 7Alkenylene group, —NH—R 15 -, -CO-R 15 -, -R 16 -O-R 17 -, -R 16 -NH-R 17 -, -R 16 -CO 2 -R 17 -, -R 16 -CO 2 -NH-R 17 -, -R 16 -CO-R 17 - or -R 16 —CO—NH—R 17 -, where R 15 is C 1 -C 7 represents an alkylene group, and R 16 is C 1 -C 3 represents an alkylene group, and R 17 is C 1 -C 5 represents an alkylene group.)
[0029] n 11 ~n 14 may be the same or different. 11 ~n 14 The closer the values of n are, the more uniform the three-dimensional structure can be, and the higher the strength. Therefore, in order to obtain a gel with high strength, it is preferable that n be the same. 11 ~n 14 If the value of is too high, the strength of the gel will be weak, and 11 ~n 14 If the value of n is too low, the gel is difficult to form due to the steric hindrance of the compound. 11 ~n 14 is an integer value of 5 to 600, preferably 25 to 250, more preferably 50 to 120, and even more preferably 110 to 120.
[0030] In the above formula (I), R 11 ~R 14 is a linker moiety connecting the functional group and the core moiety. 11 ~R 14may be the same or different, but are preferably the same in order to produce a high-strength gel having a uniform three-dimensional structure. 11 ~R 14 is C 1 -C 7 Alkylene group, C 2 -C 7 Alkenylene group, —NH—R 15 -, -CO-R 15 -, -R 16 -O-R 17 -, -R 16 -NH-R 17 -, -R 16 -CO 2 -R 17 -, -R 16 -CO 2 -NH-R 17 -, -R 16 -CO-R 17 - or -R 16 —CO—NH—R 17 - where R 15 is C 1 -C 7 represents an alkylene group. 16 is C 1 -C 3 represents an alkylene group. 17 is C 1 -C 5 represents an alkylene group.
[0031] Here, "C 1 -C 7 The term "alkylene group" means an alkylene group having 1 to 7 carbon atoms, which may be branched, and is a straight-chain C 1 -C 7 Alkylene group or C having one or more branches 2 -C 7 It means an alkylene group (having 2 to 7 carbon atoms including branches). 1 -C 7 Examples of the alkylene group include a methylene group, an ethylene group, a propylene group, and a butylene group. 1 -C 7Examples of the alkylene group are -CH2-, -(CH2)2-, -(CH2)3-, -CH(CH3)-, -(CH2)3-, -(CH(CH3))2-, -(CH2)2-CH(CH3)-, -(CH2)3-CH(CH3)-, -(CH2)2-CH(C2H5)-, -(CH2)6-, -(CH 2 )2-C(C2H5)2-, and -(CH2)3C(CH3)2CH2-.
[0032] "C 2 -C 7 The term "alkenylene group" refers to a branched or straight-chain alkenylene group having 2 to 7 carbon atoms and having one or more double bonds in the chain, and examples thereof include divalent groups having double bonds formed by removing 2 to 5 hydrogen atoms from adjacent carbon atoms of the alkylene group.
[0033] On the other hand, non-limiting specific examples of preferred polymers having an electrophilic functional group at their terminals (i.e., the second polymer in PEG-A; or PEG-B) include, for example, compounds represented by the following formula (II) having four branches of a polyethylene glycol backbone and an N-hydroxy-succinimidyl (NHS) group at their terminals.
[0034] In the above formula (II), n 21 ~n 24 may be the same or different. 21 ~n 24 The closer the values of n are, the more uniform the gel can be in a three-dimensional structure and the higher the strength, which is preferable, and it is more preferable that they are the same. 21 ~n 24 If the value of is too high, the strength of the gel will be weak, and 21 ~n 24 If the value of n is too low, the gel is difficult to form due to the steric hindrance of the compound. 21 ~n 24 is an integer value of 5 to 600, preferably 25 to 250, more preferably 50 to 120, and even more preferably 110 to 120.
[0035] In the above formula (II), R 21 ~R 24is a linker moiety connecting the functional group and the core moiety. 21 ~R 24 may be the same or different, but are preferably the same in order to produce a high-strength gel having a uniform three-dimensional structure. 21 ~R 24 are the same or different, and C 1 -C 7 Alkylene group, C 2 -C 7 Alkenylene group, —NH—R 25 -, -CO-R 25 -, -R 26 -O-R 27 -, -R 26 -NH-R 27 -, -R 26 -CO 2 -R 27 -, -R 26 -CO 2 -NH-R 27 -, -R 26 -CO-R 27 - or -R 26 —CO—NH—R 27 - where R 25 is C 1 -C 7 represents an alkylene group. 26 is C 1 -C 3 represents an alkylene group. 27 is C 1 -C 5 represents an alkylene group.
[0036] In this specification, alkylene groups and alkenylene groups may have one or more optional substituents. Examples of the substituents include, but are not limited to, alkoxy groups, halogen atoms (which may be fluorine, chlorine, bromine, or iodine atoms), amino groups, mono- or di-substituted amino groups, substituted silyl groups, acyl groups, and aryl groups. When an alkyl group has two or more substituents, they may be the same or different. The same applies to the alkyl moieties of other substituents containing an alkyl moiety (e.g., alkyloxy groups, aralkyl groups, etc.).
[0037] Furthermore, in this specification, when a functional group is defined as "optionally having a substituent," the type of the substituent, the substitution position, and the number of the substituent are not particularly limited, and when two or more substituents are present, they may be the same or different. Examples of the substituent include, but are not limited to, an alkyl group, an alkoxy group, a hydroxyl group, a carboxyl group, a halogen atom, a sulfo group, an amino group, an alkoxycarbonyl group, and an oxo group. These substituents may further have a substituent.
[0038] The content of PEG-A in the hydrogel is preferably 10 g / L or more, more preferably 20 g / L, and the content of PEG-B in the hydrogel is preferably 5 g / L or more, more preferably 15 g / L or more.
[0039] Therefore, the total content of PEG-A and PEG-B in the hydrogel is preferably 15 g / L or more, more preferably 25 g / L or more, and even more preferably 35 g / L or more.
[0040] 1-2 Polypeptide As described above, the hydrogel of the present invention contains a polypeptide for forming a second polymer network by chemical crosslinking with the PEG-B. Typically, an amino group present in the polypeptide molecule reacts with an electrophilic functional group present in a side chain or terminal of PEG-B to form a bond, thereby chemically crosslinking the polypeptide and PEG-B. The polypeptide imparts cell adhesiveness and other properties to the hydrogel.
[0041] The polypeptide may be a natural or artificial substance derived from a living organism, and may include, for example, one or more selected from the group consisting of gelatin, collagen, albumin, laminin, fibrinogen, elastin, fibronectin, and derivatives thereof. These include collagen peptides, which are proteins obtained by hydrolyzing collagen, and substances obtained by chemically modifying collagen. Preferably, the polypeptide is gelatin or a derivative thereof.
[0042] The concentration of the polypeptide in the second polymer network can be in the range of preferably 10 g / L or more and 120 g / L or less in the hydrogel.
[0043] Regarding the ratio of polypeptide to PEG-B in the second polymer network, in a preferred embodiment, the concentration of polypeptide in the entire hydrogel is 10 g / L or more and the concentration of PEG-B is 15 g / L or more; in a more preferred embodiment, the concentration of polypeptide in the entire hydrogel is 20 g / L or more and the concentration of PEG-B is 30 g / L or more.
[0044] 2. Gel Composition In another aspect, the present invention relates to a scaffold material for cell adhesion comprising the above-mentioned hydrogel. As shown in the examples below, the hydrogel of the present invention has excellent protein permeability and allows cells supported (encapsulated) in the gel to survive stably for a long period of time.
[0045] The present invention also relates to a gel composition in which cells are supported (encapsulated) in a hydrogel. Such a gel composition is useful, for example, for effectively immobilizing desired cells in a target biological tissue. As described above, the hydrogel of the present invention has an extremely short gelation time and solidifies almost instantly after the raw polymer solution is applied to the biological tissue by spraying or the like. Therefore, unlike conventional gel materials, it does not flow out before gelation, and can be applied to affected areas with complex shapes or inclined surfaces.
[0046] The cells contained in the gel composition of the present invention are not particularly limited and can be used for a wide variety of cells. The type of cells is not particularly limited and can be selected appropriately depending on the purpose. All cells can be used regardless of taxonomic classification, such as eukaryotic cells, prokaryotic cells, multicellular organism cells, or unicellular organism cells. These may be used alone or in combination of two or more types.
[0047] Examples of eukaryotic cells include animal cells, insect cells, plant cells, and fungi. These may be used alone or in combination of two or more types. The adhesive cells are not particularly limited and can be appropriately selected depending on the purpose. Examples include differentiated cells and undifferentiated cells. These may be used alone or in combination of two or more types. Examples of differentiated cells include somatic stem cells, hepatocytes (liver parenchymal cells), stellate cells, Kupffer cells, vascular endothelial cells, endothelial cells such as meatal endothelial cells and corneal endothelial cells, fibroblasts, osteoblasts, osteoclasts, periodontal ligament-derived cells, epidermal cells such as epidermal keratinocytes, tracheal epithelial cells, digestive tract epithelial cells, cervical epithelial cells, epithelial cells such as corneal epithelial cells, mammary gland cells, pericytes, muscle cells such as smooth muscle cells and cardiac muscle cells, kidney cells, pancreatic islet cells of Langerhans, nerve cells such as peripheral nerve cells and optic nerve cells, chondrocytes, and bone cells. The adhesive cells may be primary cells directly collected from tissues or organs, or may be cells that have been passaged for several generations. These may be used alone or in combination of two or more types. The undifferentiated cells are not particularly limited and can be appropriately selected depending on the purpose. Examples include undifferentiated cells such as embryonic stem cells and pluripotent mesenchymal stem cells; unipotent stem cells such as vascular endothelial progenitor cells; and induced pluripotent stem cells (iPS cells). These may be used alone or in combination of two or more types. Examples of prokaryotic cells include eubacteria and archaea. Somatic stem cells are preferred.
[0048] 3. Kit The present invention also relates to a kit for quickly preparing the above-mentioned hydrogel.
[0049] The kit of the present invention separately stores a solution X containing polymers A and B, and a solution Y containing a polypeptide and polymer C. That is, these solutions X and Y separately store polymers B and C, which are PEG polymers that form the first polymer network, and the polypeptide and polymer A that form the second polymer network. By mixing these solutions X and Y, crosslinking between the polymers progresses, and a hydrogel having these polymer networks is formed.
[0050] More specifically, in the kit of the present invention, the polymer A is a polymer having a polyethylene glycol backbone that can be chemically crosslinked with the polypeptide; the polymers B and C are a combination of polymers having polyethylene glycol backbones that can be chemically crosslinked with each other; and the gelation time of the hydrogel obtained by mixing the solutions A and B is within 10 seconds, preferably in the range of 1 to 10 seconds, wherein the gelation time is the time required for the storage modulus G' and the loss modulus G'' to reach G'=G".
[0051] Polymers B and C correspond to the first polymer and second polymer in the above-mentioned PEG-A, and preferred embodiments thereof have already been described.
[0052] Furthermore, polymer A corresponds to the above-mentioned PEG-B. Furthermore, the polypeptide contained in solution Y corresponds to the above-mentioned polypeptide that forms the second polymer network. Preferred embodiments of these are also as described above.
[0053] The concentration of polymer A in solution X is in the range of 10 to 240 g / L, preferably in the range of 20 to 120 g / L, and more preferably in the range of 30 to 90 g / L. The concentration of polypeptide in solution Y is in the range of 20 to 120 g / L, preferably in the range of 20 to 80 g / L, and more preferably in the range of 20 to 60 g / L.
[0054] The concentrations of polymer B and polymer C in solutions X and Y are each in the range of 10 to 240 g / L, preferably 20 to 150 g / L, more preferably 20 to 100 g / L, and even more preferably 20 to 60 g / L. The concentrations of polymers B and C may be the same or different as long as they satisfy the above ranges, but are preferably the same.
[0055] Solutions X and Y are adjusted so that the pH of the mixture obtained by mixing these solutions is in a range acceptable to cells (pH 5.3 or higher), preferably in the range of 6.5 to 11.5, more preferably in the range of 7.0 to 10.5, and even more preferably in the range of 7.0 to 8.5. In a typical embodiment, it is preferred that both solutions X and Y are within these pH ranges.
[0056] A pH buffer known in the art can be used to adjust the pH of solutions X and Y. For example, a citrate-phosphate buffer (CPB) can be used, and the pH can be adjusted to the above range by changing the mixing ratio of citric acid and disodium hydrogen phosphate.
[0057] The solvent in solutions X and Y is water, but in some cases, a mixed solvent containing alcohols such as ethanol or other organic solvents may be used. Preferably, solutions X and Y are aqueous solutions containing water as the sole solvent.
[0058] The volumes of Solutions X and Y in the kit of the present invention can be adjusted appropriately depending on the area and structural complexity of the biological tissue or site to which they are applied, but are typically in the range of 0.1 to 20 mL, preferably 1 to 10 mL, respectively.
[0059] In a preferred embodiment, the reaction rate of the polymer B and the polymer C is in the range of 60% to 100%. By setting the reaction rate within this range, it is possible to adjust the gelation time and other factors as desired.
[0060] The means for mixing solutions X and Y by dropwise addition can be, for example, a two-liquid mixing syringe such as that disclosed in International Publication WO 2007 / 083522. The temperatures of the two liquids during mixing are not particularly limited, as long as each polymer is dissolved and each liquid has fluidity. For example, the temperatures of the two liquids may be different, but it is preferable that the temperatures are the same because this facilitates mixing of the two liquids.
[0061] The kit of the present invention may also include a means for spraying solutions X and Y onto a predetermined area using a sprayer. Such a means can be a sprayer that stores solutions X and Y separately. Any sprayer known in the art can be used as appropriate, and a medical sprayer is preferred. Therefore, such a sprayer can be used as the container in the kit of the present invention. In this case, one aspect of the present invention is a medical device, preferably a sprayer, that stores solutions X and Y.
[0062] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.
[0063] Materials: Gelatin derived from pig skin (APAT, M w = 60 kg / mol) and collagen casing derived from bovine skin were purchased from Nippi Inc. (Tokyo, Japan). M, terminally functionalized with N-hydroxysuccinimide (NHS), maleimide (MA), or thiol (SH) groups, was used. w = 10 kg / mol of 4-arm polyethylene glycol (PEG) (PEG-NHS, PEG-MA, respectively) 、 and PEG-SH) were purchased from SINOPEG Biotech Co., Ltd. (Fujian, China). D-PBS(-) (PBS), Dulbecco's Modified Eagle Medium (DMEM), penicillin / streptomycin (PS), trypsin-EDTA (0.05%), fetal bovine serum (FBS), LIVE / DEAD® Viability / Cytotoxicity Kit, Calcein Blue AM, and Cellstain were purchased from SINOPEG Biotech Co., Ltd. (Fujian, China). R-PI solution and fluorescein isothiocyanate-conjugated bovine serum albumin (FITC-BSA) were purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA). Collagenase from Clostridium histolyticum was purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium hydroxide (NaOH) was purchased from Fujifilm Wako Pure Chemical Industries, Ltd. (Tokyo, Japan). Blue ink (Waterman Mysterious Blue Ink) for visualizing hydrogel components was purchased from Waterman Pen Company (New York, NY, USA). Cyanoacrylate adhesive was purchased from Toagosei Co., Ltd. (Tokyo, Japan).
[0064] Equipment: A 0.22 μm filter (Minisart, RC15-AC, Sartorius AG, Göttingen, Germany), a rheometer (MCR 301, Anton Paar GmbH, North Ryde, Australia), a tensile tester (Autograph AG-X plus, Shimadzu Corporation, Kyoto, Japan), a fluorescence microscope (BZ-X710, Keyence Corp., Osaka, Japan), and a confocal laser scanning microscope (CLSM, LSM 800, Carl Zeiss AG, Jena, Germany) were used in the experiments.
[0065] 1. Preparation of Polymer Solutions and Gelation Process Polymer components were dissolved in PBS at the concentrations shown in Table 1 below to prepare various polymer solutions A and B. Polymer solution A contained gelatin and a 4-branched polyethylene glycol having an SH group at its terminal (PEG-SH). Polymer solution B contained a 4-branched polyethylene glycol having an N-hydroxysuccinimide group at its terminal (PEG-NHS) and a 4-branched polyethylene glycol having a maleimide group at its terminal (PEG-MA). Here, gelatin and PEG-NHS (collectively referred to as the "GP pair") can form a hydrogel (GP gel) by crosslinking with each other, and PEG-SH and PEG-MA (collectively referred to as the "PP pair") can also form another hydrogel (PP gel) by crosslinking with each other.
[0066] The two prepared polymer solutions A and B were mixed in a volume ratio of 1:1, and a gelation test was carried out. The mixed gelling solution was poured into a glass vial, and the time required to reach this point when the solution lost fluidity when tilted was defined as the gelling point, and the time required to reach this point was defined as the gelling time "t gel " was observed.
[0067] As a result, as shown in Table 1, in Examples 1 to 11, gels were formed in a short time of within a few seconds. On the other hand, no gel formation was observed in Comparative Examples 1 to 4 and 18. Furthermore, in Comparative Examples 5 to 17, although gel formation was observed, it took one minute or more for gelation to occur, and in some cases, cloudiness was observed after mixing.
[0068] 2. Verification of Gel Formation Behavior Next, the gel formation behavior when polymer solutions A and B were mixed was verified.
[0069] <Rheological Characterization> The storage modulus (G') and loss modulus (G") were measured using the following procedure. Polymer solution A was placed on the bottom plate of the rheometer, and an equal volume of polymer solution B was added. The measurement plate (PP25, diameter 3 mm) installed on top of the rheometer was set 0.3 mm from the bottom plate. The experimental parameters were a temperature of 25°C, a shear amplitude of 1%, and an oscillation frequency of 1.0 Hz. The changes in the storage modulus (G') and loss modulus (G") of the gelled solution were measured over time.
[0070] <Shear Modulus> The shear modulus was measured as follows: Polymer solution A was poured into a silicone mold (35 mm diameter, 1 mm height) and mixed with an equal volume of polymer solution B. After 24 hours of incubation at 25°C, the formed hydrogel was gently removed from the mold and placed on the bottom plate of the rheometer. A measuring plate (PP25) was placed near the sample until a force of 1.5 N was detected. G' was measured at 25°C over a strain range of 0.1 to 10% and an angular frequency of 10 Hz.
[0071] First, to confirm the hydrogel-forming ability of the GP pair, which has an inherently slow solidification rate, an 80 g / L gelatin solution and a 120 g / L PEG-NHS solution were separately prepared using neutral phosphate-buffered saline (PBS) (Comparative Example 16). These two solutions were mixed in a 1:1 volume ratio, and the concentration of the GP component (C GP ) = 100 g / L. A hydrolysis-resistant amide bond was formed between gelatin and PEG-NHS, and the mixed solution solidified over time (Figure 1(A)). GP By changing the vial tilting method, t gel The higher C GP So, a shorter t gel However, because high concentrations can be cytotoxic, a relatively low concentration (C GP = 50 g / L) was selected as a representative example (Comparative Example 17). GP Gelation did not occur at a concentration of 25 g / L, likely due to the low concentration. To obtain more quantitative results, the dynamic viscoelastic properties of a representative GP hydrogel were measured (Fig. 1(C)). During the first few minutes, it was clear that the storage modulus (G') was less than the loss modulus (G"). This indicated that the material took several minutes to solidify, during which time it would flow off an inclined surface if applied. Subsequently, the relationship reversed to G' > G" over time, confirming gelation.
[0072] Next, we investigated the gelation behavior of the other pair, the PP pair, which has a relatively short gelation time (Reference Examples 1 to 4). Each PEG was prepared separately in PBS, and then the two solutions were mixed to form a hydrogel similar to that of GP (Figure 2(A)). Here, a thioether bond was formed between the sulfhydryl group and the maleimide group. The gelation behavior of the other pair, the PP pair, was investigated (Reference Examples 1 to 4 in Table 1). PP ) and t gel The value was obtained. PP Solidification within 5 seconds was observed at concentrations ≥ 10 g / L (Figure 1E). PP ≧Gelation at 10 g / L was difficult. Next, the dynamic viscoelasticity of a representative PP hydrogel was measured (Figure 1F). The gelation point (i.e., the crossover between G′ and G″) was rapidly reached, indicating that the crosslinking reaction was extremely fast at neutral pH. Therefore, PP hydrogels may be promising carriers for the delivery of GP hydrogels, which themselves exhibit slow hydrogel formation.
[0073] Next, when the polymer solution of Example 3 was mixed (Figure 3(A)), instantaneous coagulation was observed. Furthermore, dynamic viscoelastic measurements revealed a G' > G" relationship immediately after mixing (Figure 3(b)). This PP hydrogel-like profile indicated that crosslinking of the PP component was not inhibited by the presence of the GP component. Furthermore, a significant increase in G' was observed after several minutes. Considering that this increase in G' was also observed in the GP hydrogel, it is likely that the GP network formed over time as an interpenetrating network (IPN) within the single PEG network. Furthermore, the equilibrium G' values after gelation followed the order: hydrogel derived from GP and PP components (GP / PP hydrogel) > GP hydrogel > PP hydrogel (Figure 4).
[0074] This result indicates that the first and second IPNs are physically entangled, thereby increasing the elastic modulus of the composite material compared to the elastic modulus of each component alone. Therefore, it was suggested that these two polymer solutions solidify instantly when sprayed onto a specific location using a sprayer (Figure 5). Therefore, by applying the polymer solutions of Examples 1 to 11, the gel material can be applied without flowing out, regardless of the shape of the target tissue.
[0075] To confirm the presence of IPN, a stepwise degradation test was performed using a modified GP / PP hydrogel (hereafter referred to as GP / PP(ester) hydrogel) in which PEG-MA was replaced with PEG-MA(ester) containing a hydrolyzable ester moiety (Fig. 6). Prior to testing the GP / PP(ester) hydrogel, the GP and PP(ester) hydrogels were immersed in collagenase and alkaline aqueous solutions, respectively, to confirm the hydrogel degradation by these solutions (Fig. 6).
[0076] Next, the GP / PP(ester) hydrogel was immersed in a collagenase solution, the enzyme reaction was stopped with neutral PBS, and the hydrogel was then immersed in an alkaline aqueous solution (NaOH). As shown in the right panel of Figure 6, the equilibrium swelling degree (Q) increased with time in the collagenase solution, whereas Q remained nearly constant in PBS. In the subsequent alkaline aqueous solution step, Q increased rapidly and then disappeared macroscopically. This is because the balance between osmotic pressure and restoring force was disrupted when the GP network was cleaved in the first collagenase step, resulting in an increase in Q (i.e., swelling due to degradation).
[0077] In contrast, as shown in the right panel of Figure 6, the PP(ester)-derived PEG network remained unchanged in the collagenase environment, resulting in a finite degree of Q and maintaining the solidity of the hydrogel. In an alkaline solution, the hydrolyzable esters present in the PP(ester) network were cleaved, disrupting the balance between osmotic pressure and restoring force again, resulting in an increase in Q. Finally, the entire hydrogel network structure was lost and disappeared macroscopically.
[0078] We also performed experiments in which hydrogels were immersed in an alkaline solution, followed by PBS, and finally collagenase. Q increased with time in the alkaline solution, remained stable in neutral PBS, and then rapidly decreased in the collagenase solution, ultimately resulting in the disappearance of the hydrogel. This contrasts with the previous hydrogel pattern, in which the hydrolyzable PP (ester) network was first cleaved in the alkaline solution, the GP network maintained the hydrogel solid, and the subsequent collagenase solution enzymatically digested the gelatin, resulting in the disappearance of the gel. This degradation behavior, accompanied by a decrease in Q, is observed when the polymer network cleavage occurs preferentially from the surface of the hydrogel due to the relatively high enzyme concentration in the outer solution. These results indicate that the GP / PP (ester) hydrogel has an IPN structure derived from the GP and PP (ester) networks.
[0079] These results demonstrate that hydrogels with a GP network can be instantly formed in situ by spraying, even while maintaining a neutral pH of the polymer solution. The formed hydrogels were completely degraded when both the GP and PP networks were cleaved. The GP network was digested by collagenase, which is ubiquitously expressed in vivo, and the PP (ester) network was hydrolyzed under physiological conditions. Therefore, the hydrogels of the present invention are biodegradable in vivo.
[0080] 4. Evaluation of Cell Adhesion Properties To clarify the tissue adhesion properties of the hydrogel of the present invention, the lap shear strength of the hydrogel on the collagen casing was evaluated.
[0081] The specific procedure is shown in Figure 7. The expanded collagen casing was pre-fixed to a glass substrate with cyanoacrylate adhesive. Two identical substrates with collagen casings were prepared, and hydrogel was applied between the collagen casings. The specimens were then tensioned using a tensile tester to obtain the lap shear strength versus displacement, and the lap shear strength at break was calculated (Figure 8).
[0082] Here, the lap shear strength is F / S ini where F is the applied force and S ini is 10.4 cm 2 The initial adhesive area is F. The lap shear strength at break is F max / S ini wherein F max is the maximum force given, and S ini is 10.4 cm 2 is.
[0083] As shown in the right panel of Figure 8, the PP hydrogel did not exhibit significant lap shear strength. This is due to the lack of cysteine residues (i.e., maleimide-reactive sulfhydryl groups) in animal-derived collagen, and the reaction between maleimide groups and amino groups is only effective under alkaline conditions. In contrast to the PP hydrogel, a significant increase in lap shear strength versus displacement was observed in the two groups containing the GP hydrogel. This strongly suggests that the NHS groups reacted with gelatin to form a polymer network within the GP hydrogel, forming chemical bonds with the amino groups on the surface of the collagen casing. This result is consistent with previous studies that identified hydrogels composed of gelatin and PEG-NHS that adhere to biological tissue. The GP / PP hydrogel of the present invention exhibited similar lap shear strength to the GP hydrogel. Considering that no adhesion was observed with the PP hydrogel, it is likely that some of the PP hydrogel crosslinked with the collagen casing of the GP / PP hydrogel. These results indicate that by forming both GP hydrogel and PP hydrogel, it is possible to obtain both the instant solidification property derived from PP hydrogel and the tissue adhesive property derived from GP hydrogel.
[0084] 5. Encapsulation of Cells in Hydrogels To evaluate the cytocompatibility of the hydrogels of the present invention, human mesenchymal stem cells (hMSCs) were encapsulated in the hydrogels and cultured in a standard medium, and the cell morphology was observed ( FIG. 9(A) ). The percentage of live cells was calculated from the obtained fluorescent images ( FIG. 9(B) ). The specific experimental procedure is as follows:
[0085] <Cell culture on hydrogels formed by spraying> hMSCs (passage 2) were cultured in 10 mL of DMEM (10% FBS and 1% PS) in a 10 cm dish (Corning Inc., Corning, NY, USA) at 37°C under a 5% CO2 atmosphere for 1 week. The medium was changed every 2-3 days to ensure nutrient supply. Polymer solutions A and B were sterilized using a 0.22 μm filter, and the sprayer (MIS Spray Applicator, Medmix AG, Baar, Switzerland) was disinfected with 70% ethanol and then washed with DMEM. hMSCs (passage 3) were cultured at 5.0 × 10 5 The cells were suspended in polymer solution A at a cell density of 1000 cells / mL. Solution A and solution B containing the suspended cells were loaded into separate 5 mL syringes and sprayed onto each well of a 12-well cell culture plate. The sprayed solutions were incubated in 5% CO 2 The resulting hydrogel was incubated at 37°C for 30 minutes. The final volume and cell number of the hydrogel were 1 mL and 2.5 × 10 cells, respectively. 5 The prepared hydrogel was immersed in 2 mL of DMEM and incubated for 1 week. The medium was changed every 2-3 days.
[0086] Observation of cell morphology and viability. DMEM containing 1 μM calcein AM and 2 μM ethidium homodimer was prepared according to the manufacturer's protocol. hMSCs were incubated in the hydrogel for 0, 4, and 7 days, and then further incubated in the prepared DMEM at 37°C and 5% CO2 for 10 minutes at each time point. The hydrogels were then washed three times with PBS. Cells encapsulated in the hydrogels were observed under a fluorescence microscope, and the number of live and dead cells was counted using Image J software. Cell viability was calculated as the ratio of live cells to total cells.
[0087] As shown in Figure 9, in the case of cell-encapsulated GP hydrogel, all cells were spherical on day 0, but some cells became elongated on day 3, and the proportion of elongated cells further increased on day 7. The high cell viability (>90%) indicated that the shear stress caused by spraying was not affected. The morphological changes and cell viability were similar to those reported previously for gelatin and PEG hydrogels, confirming the validity of this cell culture protocol.
[0088] We also tested cell-encapsulated PP hydrogels in the same culture system. Similar to GP hydrogels, cells were spherical immediately after preparation, but unlike GP hydrogels, they remained spherical up to day 7. A slight decrease in cell viability was also observed. Because hMSCs were unable to adhere or spread on pure PEG hydrogels, this may be due to anoikis (apoptotic cell death caused by insufficient cell-matrix interactions). However, cell viability exceeded 80%, suggesting that the crosslinking reaction of PP hydrogels was not highly cytotoxic, making them a promising carrier material for GP hydrogels.
[0089] The cell viability of the GP / PP(ester) hydrogel of the present invention was comparable to that of GP hydrogel alone (>90%), and the cell morphology on day 7 was similar to that of GP hydrogel, with some cells elongating in both cases. These results indicate that the cytocompatibility and cell adhesive properties of GP hydrogel are maintained even when it contains PP hydrogel components.
[0090] Next, we evaluated the permeability of GP / PP(ester) hydrogels. In this assay, fluorescein isothiocyanate (FITC)-labeled bovine serum albumin (BSA) was added to the culture medium (i.e., outside the hydrogel) (Figure 10, left panel). This compound is known to cross the cell membrane and enter the cytoplasm via endocytosis. The specific procedure is as follows.
[0091] DMEM containing 2 μM calcein blue and 2 μM PI was prepared. FITC-BSA was added to the prepared DMEM at 0.1 g / L. Cell-encapsulated GP / PP hydrogels were prepared and incubated in DMEM containing FITC-BSA for 30 minutes, followed by incubation in DMEM containing calcein blue and PI for 10 minutes at 37°C under 5% CO2. The hydrogels were then washed three times with PBS and observed by CLSM.
[0092] The results are shown in the right panel of Figure 10. After the addition of BSA, cross-sectional images of cells taken with a confocal microscope showed that the cytoplasm turned green, indicating that BSA diffused into the hydrogel and reached the cytoplasm of the encapsulated cells. Because BSA is a protein with a molecular weight of approximately 66 kDa, other proteins with similar or lower molecular weights are likely to be able to freely pass through the hydrogel. Such excellent permeability is important for cell medicine, not only for cell survival but also for therapeutic effects from proteins secreted by cells such as hMSCs.
[0093] These results demonstrate that the hydrogels containing two components, 1) a tissue-adhesive gelatin / PEG hydrogel and 2) a fast-setting PEG hydrogel, can be sprayed and solidified instantly, and exhibit excellent cell adhesion. Furthermore, human mesenchymal stem cells (hMSCs) were successfully encapsulated in the hydrogels, demonstrating excellent cell viability (>90%) within the hydrogels. Furthermore, the hydrogels were shown to be permeable to proteins. These results demonstrate that the hydrogels of the present invention can immobilize cells secreting beneficial proteins in various biological tissues, potentially becoming a fundamental tool in the field of cell medicine.
Claims
1. A hydrogel comprising a first polymer network formed by chemically crosslinking two or more types of polymers (PEG-A) having a polyethylene glycol backbone, and a second polymer network formed by chemically crosslinking a polypeptide and a polymer (PEG-B) having a polyethylene glycol backbone.
2. The hydrogel of claim 1, having a gelation time in the range of 10 seconds or less, said gelation time being the time required for the storage modulus G' and loss modulus G" to reach G'=G".
3. The hydrogel described in claim 1, wherein the concentration of the polypeptide in the second polymer network is 10 g / L or more and 120 g / L or less in the hydrogel.
4. The hydrogel described in claim 1, wherein the total content of polymers having a polyethylene glycol backbone (PEG-A and PEG-B) in the hydrogel is 15 g / L or more.
5. The hydrogel of claim 1, wherein the first polymer network has cleavable sites selected from the group consisting of ester bonds, thioester bonds, disulfide bonds, phosphate ester bonds, sulfonate ester bonds, and combinations thereof.
6. The hydrogel described in claim 1, wherein the polymer having a polyethylene glycol backbone (PEG-A) in the first polymer network includes a first polymer having a total of two or more nucleophilic functional groups at its side chains or ends, and a second polymer having a total of two or more electrophilic functional groups at its side chains or ends.
7. The hydrogel described in claim 1, wherein the polymer having a polyethylene glycol backbone (PEG-B) in the second polymer network has a total of two or more electrophilic functional groups at the side chains or ends that can react with amino groups present in the polypeptide molecule to form amide bonds or urethane bonds.
8. The hydrogel according to claim 1, wherein the polypeptide is one or more selected from the group consisting of gelatin, collagen, albumin, laminin, fibrinogen, elastin, fibronectin, or derivatives thereof.
9. The hydrogel described in claim 1, wherein the concentration of the polypeptide in the hydrogel is 10 g / L or more, and the concentration of the polymer having a polyethylene glycol backbone (PEG-B) in the second polymer network is 15 g / L or more.
10. The hydrogel according to claim 1, wherein the pH of the solvent contained in the hydrogel is in the range of 6.5 to 11.
5.
11. A scaffold material for cell adhesion comprising the hydrogel according to any one of claims 1 to 10.
12. A gel composition comprising the hydrogel according to any one of claims 1 to 10 and cells supported therein.
13. The gel composition of claim 12, wherein the cells are somatic stem cells.
14. A kit for rapidly preparing a hydrogel, comprising: a solution X containing polymers A and B; and a solution Y containing a polypeptide and polymer C, which are separately stored; the polymer A is a polymer having a polyethylene glycol backbone capable of being chemically crosslinked with the polypeptide; and the polymers B and C are a combination of polymers having polyethylene glycol backbones capable of being chemically crosslinked with each other; and the gelation time of the hydrogel obtained by mixing the solutions X and Y is within 10 seconds, wherein the gelation time is the time required for the storage modulus G' and the loss modulus G'' to reach G' = G".
15. The kit according to claim 14, wherein the polymer A has, at its side chain or end, a total of two or more electrophilic functional groups capable of reacting with an amino group present in the polypeptide molecule to form an amide bond or a urethane bond.
16. The kit according to claim 14, wherein the polymers B and C are a combination of a polymer having a total of two or more nucleophilic functional groups at the side chain or end and a polymer having a total of two or more electrophilic functional groups at the side chain or end.
17. The kit according to claim 14, wherein the polypeptide in solution Y is one or more selected from the group consisting of gelatin, collagen, albumin, laminin, fibrinogen, elastin, fibronectin, or derivatives thereof.
18. The kit according to claim 14, wherein the reaction rate of said polymer B and said polymer C is in the range of 60% to 100%.
19. The kit according to claim 14, for spraying said solutions X and Y onto a predetermined area with a sprayer.
20. The kit of claim 14, wherein solutions X and Y are each contained in a separate sprayer.
Citation Information
Patent Citations
Gel-forming composition for medical use, devices for the application of the composition, and drug release controlling carrier
WO2007083522A1
Hydrogel composition
JP2020150846A
Gel for treating venous insufficiency or varicose vein, and gel generating kit
JP2024087284A
Cited By
Structure and method for transplanting tumor tissue
WO2025187699A1
